Evidence map›Paper›PMID 38654325›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

Tumor-suppressive miR-4732-3p is sorted into fucosylated exosome by hnRNPK to avoid the inhibition of lung cancer progression.

Wanzhen Zhuang, Chengxiu Liu, Yilin Hong, Yue Zheng, Minjian Huang, Haijun Tang, Lilan Zhao, Zhixin Huang, Mingshu Tu, Lili Yu and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Exosome miRNA sorting controlled by RNA-binding protein-motif interactions.Extracellular vesicles and circulating nucleic acids · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Cancers · 2024
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Wanzhen Zhuang *Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Chengxiu Liu *State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361102, China.
Yilin Hong *State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361102, China.
Yue ZhengShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Minjian HuangShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Haijun TangShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Lilan ZhaoShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Zhixin HuangDepartment of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, China.
Mingshu TuShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Lili YuShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Jianlin ChenShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Yi ZhangShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Xiongfeng ChenShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China.
Fan LinDepartment of Geriatric Medicine, Fujian Provincial Hospital, Fuzhou, 350001, China.
Qi GaoInstitute of Future Technology, Beijing Hotgen Biotech Co., Ltd, Beijing, 102600, China.
Chundong YuShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China. cdyu@xmu.edu.cn.ORCID http://orcid.org/0000-0002-4141-8345
Yi HuangShengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China. hyi8070@126.com.
Fujian Medical University · CNXiamen University · CNFujian Provincial Hospital · CNFujian University of Traditional Chinese Medicine · CN

Funding

Joint Fund of Science and Technology Innovation of Fujian Province 2021Y9024Key Project of Natural Science Foundation of Fujian Province 2022J02048Medical Vertical Project of Fujian Province 2020CXB001
6 · The paper itself

Abstract

backgroundAberrant fucosylation observed in cancer cells contributes to an augmented release of fucosylated exosomes into the bloodstream, where miRNAs including miR-4732-3p hold promise as potential tumor biomarkers in our pilot study. However, the mechanisms underlying the sorting of miR-4732-3p into fucosylated exosomes during lung cancer progression remain poorly understood.

methodsA fucose-captured strategy based on lentil lectin-magnetic beads was utilized to isolate fucosylated exosomes and evaluate the efficiency for capturing tumor-derived exosomes using nanoparticle tracking analysis (NTA). Fluorescence in situ hybridization (FISH) and qRT-PCR were performed to determine the levels of miR-4732-3p in non-small cell lung cancer (NSCLC) tissue samples. A co-culture system was established to assess the release of miRNA via exosomes from NSCLC cells. RNA immunoprecipitation (RIP) and miRNA pull-down were applied to validate the interaction between miR-4732-3p and heterogeneous nuclear ribonucleoprotein K (hnRNPK) protein. Cell functional assays, cell derived xenograft, dual-luciferase reporter experiments, and western blot were applied to examine the effects of miR-4732-3p on MFSD12 and its downstream signaling pathways, and the impact of hnRNPK in NSCLC.

resultsWe enriched exosomes derived from NSCLC cells using the fucose-captured strategy and detected a significant upregulation of miR-4732-3p in fucosylated exosomes present in the serum, while its expression declined in NSCLC tissues. miR-4732-3p functioned as a tumor suppressor in NSCLC by targeting 3'UTR of MFSD12, thereby inhibiting AKT/p21 signaling pathway to induce cell cycle arrest in G2/M phase. NSCLC cells preferentially released miR-4732-3p via exosomes instead of retaining them intracellularly, which was facilitated by the interaction of miR-4732-3p with hnRNPK protein for selective sorting into fucosylated exosomes. Moreover, knockdown of hnRNPK suppressed NSCLC cell proliferation, with the elevated levels of miR-4732-3p in NSCLC tissues but the decreased expression in serum fucosylated exosomes.

conclusionsNSCLC cells escape suppressive effects of miR-4732-3p through hnRNPK-mediated sorting of them into fucosylated exosomes, thus supporting cell malignant properties and promoting NSCLC progression. Our study provides a promising biomarker for NSCLC and opens a novel avenue for NSCLC therapy by targeting hnRNPK to prevent the "exosome escape" of tumor-suppressive miR-4732-3p from NSCLC cells.

Indexed as

Carcinoma, Non-Small-Cell LungExosomesFucoseHeterogeneous-Nuclear Ribonucleoprotein KLung NeoplasmsMicroRNAsAnimalsBiomarkers, TumorCell Cycle CheckpointsCell ProliferationDisease ProgressionDown-RegulationGenes, Tumor SuppressorGlycosylationHumansMembrane ProteinsBiomarkers, TumorFucoseHeterogeneous-Nuclear Ribonucleoprotein KHNRNPK protein, humanMembrane ProteinsMFSD12 protein, humanMicroRNAsMIRN4732 microRNA, humanExosome escapeFucosylated exosomehnRNPKMFSD12miR-4732-3p

Identifiers

PMID38654325
PMCPMC11036635
OpenAlexW4395047771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.